Cargando…
Prognostic factors in patients with acute ischemic stroke treated with intravenous tissue plasminogen activator: The first study among Iranian patients
Background: Tissue plasminogen activator (tPA) has been long approved as an efficacious treatment in patients with acute ischemic stroke (AIS); however, due to some serious complications, particularly intracranial hemorrhage (ICH), many physicians are still reluctant to use it liberally. This study...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tehran University of Medical Sciences
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6121208/ https://www.ncbi.nlm.nih.gov/pubmed/30186557 |
_version_ | 1783352415382142976 |
---|---|
author | Sadeghi-Hokmabadi, Elyar Yazdchi, Mohammad Farhoudi, Mehdi Sadeghi, Homayoun Taheraghdam, Aliakbar Rikhtegar, Reza Aliyar, Hannaneh Mohammadi-Fallah, Sahar Asadi, Rogayyeh Mehdizadeh-Far, Elham Ghaemian, Neda |
author_facet | Sadeghi-Hokmabadi, Elyar Yazdchi, Mohammad Farhoudi, Mehdi Sadeghi, Homayoun Taheraghdam, Aliakbar Rikhtegar, Reza Aliyar, Hannaneh Mohammadi-Fallah, Sahar Asadi, Rogayyeh Mehdizadeh-Far, Elham Ghaemian, Neda |
author_sort | Sadeghi-Hokmabadi, Elyar |
collection | PubMed |
description | Background: Tissue plasminogen activator (tPA) has been long approved as an efficacious treatment in patients with acute ischemic stroke (AIS); however, due to some serious complications, particularly intracranial hemorrhage (ICH), many physicians are still reluctant to use it liberally. This study sought to find potential prognostic factors in patients with AIS treated with tPA. Methods: A retrospective, hospital-bases observational study was conducted. Consecutively, a total of 132 patients with AIS treated with intravenous tPA, form June 2011 to July 2015 were enrolled. Inclusion and exclusion criteria were based on updated guidelines. Probable prognostic variables were examined separately in three distinct groups; the occurrence of ICH within 24 hours after treatment, poor 3-month outcome on the basis of modified Rankin Scale (mRS) and 3-month mortality. Results: Patients were 83 men (62.9%) and 49 women (37.1%) with a median age of 66 years [interquartile range (IQR)of 55-72]. Any type of hemorrhage, symptomatic hemorrhage [based on the European Cooperative Acute Stroke Study III (ECASS III) definition] within 24 hours posttreatment, poor 3-month outcome (mRS 3-6), and 3-month mortality were documented in 10.6%, 4.5%, 53.2%, and 23.6% of patients, respectively. Increased baseline blood glucose was a significant but dependent predictor of hemorrhage within the first 24 hours posttreatment. Dependent predictors of a 3-month poor outcome were high age, the National Institutes of Health Stroke Scale (NIHSS) at baseline, decreased admitting glomerular filtration rate (GFR), and the presence of atrial fibrillation (AF) rhythm, and ICH within 24 hours posttreatment. Only age [Odds ratio (OR) adjusted 1.05] and initial NIHSS (OR adjusted 1.23), however, were recognized as the independent variables in this regard. The only independent predictor of 3-month mortality was the initial NIHSS (OR adjusted 1.18). Conclusion: According to the findings of the present study, advanced age and high baseline NIHSS are two independent prognostic factors in patients with AIS treated with tPA. |
format | Online Article Text |
id | pubmed-6121208 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Tehran University of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-61212082018-09-05 Prognostic factors in patients with acute ischemic stroke treated with intravenous tissue plasminogen activator: The first study among Iranian patients Sadeghi-Hokmabadi, Elyar Yazdchi, Mohammad Farhoudi, Mehdi Sadeghi, Homayoun Taheraghdam, Aliakbar Rikhtegar, Reza Aliyar, Hannaneh Mohammadi-Fallah, Sahar Asadi, Rogayyeh Mehdizadeh-Far, Elham Ghaemian, Neda Iran J Neurol Original Article Background: Tissue plasminogen activator (tPA) has been long approved as an efficacious treatment in patients with acute ischemic stroke (AIS); however, due to some serious complications, particularly intracranial hemorrhage (ICH), many physicians are still reluctant to use it liberally. This study sought to find potential prognostic factors in patients with AIS treated with tPA. Methods: A retrospective, hospital-bases observational study was conducted. Consecutively, a total of 132 patients with AIS treated with intravenous tPA, form June 2011 to July 2015 were enrolled. Inclusion and exclusion criteria were based on updated guidelines. Probable prognostic variables were examined separately in three distinct groups; the occurrence of ICH within 24 hours after treatment, poor 3-month outcome on the basis of modified Rankin Scale (mRS) and 3-month mortality. Results: Patients were 83 men (62.9%) and 49 women (37.1%) with a median age of 66 years [interquartile range (IQR)of 55-72]. Any type of hemorrhage, symptomatic hemorrhage [based on the European Cooperative Acute Stroke Study III (ECASS III) definition] within 24 hours posttreatment, poor 3-month outcome (mRS 3-6), and 3-month mortality were documented in 10.6%, 4.5%, 53.2%, and 23.6% of patients, respectively. Increased baseline blood glucose was a significant but dependent predictor of hemorrhage within the first 24 hours posttreatment. Dependent predictors of a 3-month poor outcome were high age, the National Institutes of Health Stroke Scale (NIHSS) at baseline, decreased admitting glomerular filtration rate (GFR), and the presence of atrial fibrillation (AF) rhythm, and ICH within 24 hours posttreatment. Only age [Odds ratio (OR) adjusted 1.05] and initial NIHSS (OR adjusted 1.23), however, were recognized as the independent variables in this regard. The only independent predictor of 3-month mortality was the initial NIHSS (OR adjusted 1.18). Conclusion: According to the findings of the present study, advanced age and high baseline NIHSS are two independent prognostic factors in patients with AIS treated with tPA. Tehran University of Medical Sciences 2018-01-05 /pmc/articles/PMC6121208/ /pubmed/30186557 Text en Copyright © 2015 Iranian Neurological Association, and Tehran University of Medical Sciences This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Sadeghi-Hokmabadi, Elyar Yazdchi, Mohammad Farhoudi, Mehdi Sadeghi, Homayoun Taheraghdam, Aliakbar Rikhtegar, Reza Aliyar, Hannaneh Mohammadi-Fallah, Sahar Asadi, Rogayyeh Mehdizadeh-Far, Elham Ghaemian, Neda Prognostic factors in patients with acute ischemic stroke treated with intravenous tissue plasminogen activator: The first study among Iranian patients |
title | Prognostic factors in patients with acute ischemic stroke treated with intravenous tissue plasminogen activator: The first study among Iranian patients |
title_full | Prognostic factors in patients with acute ischemic stroke treated with intravenous tissue plasminogen activator: The first study among Iranian patients |
title_fullStr | Prognostic factors in patients with acute ischemic stroke treated with intravenous tissue plasminogen activator: The first study among Iranian patients |
title_full_unstemmed | Prognostic factors in patients with acute ischemic stroke treated with intravenous tissue plasminogen activator: The first study among Iranian patients |
title_short | Prognostic factors in patients with acute ischemic stroke treated with intravenous tissue plasminogen activator: The first study among Iranian patients |
title_sort | prognostic factors in patients with acute ischemic stroke treated with intravenous tissue plasminogen activator: the first study among iranian patients |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6121208/ https://www.ncbi.nlm.nih.gov/pubmed/30186557 |
work_keys_str_mv | AT sadeghihokmabadielyar prognosticfactorsinpatientswithacuteischemicstroketreatedwithintravenoustissueplasminogenactivatorthefirststudyamongiranianpatients AT yazdchimohammad prognosticfactorsinpatientswithacuteischemicstroketreatedwithintravenoustissueplasminogenactivatorthefirststudyamongiranianpatients AT farhoudimehdi prognosticfactorsinpatientswithacuteischemicstroketreatedwithintravenoustissueplasminogenactivatorthefirststudyamongiranianpatients AT sadeghihomayoun prognosticfactorsinpatientswithacuteischemicstroketreatedwithintravenoustissueplasminogenactivatorthefirststudyamongiranianpatients AT taheraghdamaliakbar prognosticfactorsinpatientswithacuteischemicstroketreatedwithintravenoustissueplasminogenactivatorthefirststudyamongiranianpatients AT rikhtegarreza prognosticfactorsinpatientswithacuteischemicstroketreatedwithintravenoustissueplasminogenactivatorthefirststudyamongiranianpatients AT aliyarhannaneh prognosticfactorsinpatientswithacuteischemicstroketreatedwithintravenoustissueplasminogenactivatorthefirststudyamongiranianpatients AT mohammadifallahsahar prognosticfactorsinpatientswithacuteischemicstroketreatedwithintravenoustissueplasminogenactivatorthefirststudyamongiranianpatients AT asadirogayyeh prognosticfactorsinpatientswithacuteischemicstroketreatedwithintravenoustissueplasminogenactivatorthefirststudyamongiranianpatients AT mehdizadehfarelham prognosticfactorsinpatientswithacuteischemicstroketreatedwithintravenoustissueplasminogenactivatorthefirststudyamongiranianpatients AT ghaemianneda prognosticfactorsinpatientswithacuteischemicstroketreatedwithintravenoustissueplasminogenactivatorthefirststudyamongiranianpatients |